



**Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. *Blood*. 2020;136(18):2027–2037.**

In supplemental Table 3, in the second of the 3 column subheadings under “Relapsed/Refractory” and “Total,” “160 mg qd” should read “160 mg bid.” In supplemental Table 5, row 7, “TEAE” should read “treatment-related TEAE.” The corrected supplemental data file has been placed in the online version of the article.

DOI 10.1182/blood.2021010665

© 2021 by The American Society of Hematology

---

**Kundumani-Sridharan V, Niu J, Wang D, et al. 15(S)-hydroxyeicosatetraenoic acid–induced angiogenesis requires Src-mediated Egr-1–dependent rapid induction of FGF-2 expression. *Blood*. 2010;115(10):2105–2116.**

We performed an experiment to study the role of Egr1 and Src on 15(S)-hydroxyeicosatetraenoic acid [15(S)-HETE]–induced human dermal microvascular endothelial cell tube formation. The data were split between Figure 1D (page 2107) and Figure 2D (page 2108) for better presentation, and an overlapping image for Ad-GFP + 15(S)-HETE treatment was inserted inadvertently in both Figure 1D and Figure 2D. Since it is one of several images of the Ad-GFP + 15(S)-HETE treatment group that were used for comparing the effects of dn-Egr1 + 15(S)-HETE and dn-Src + 15(S)-HETE treatments from the same experiment and the bar graphs in the figures show quantitative data of several replicates with statistical analysis, it does not affect the results or the conclusions of the study.

DOI 10.1182/blood.2021010742

© 2021 by The American Society of Hematology